{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:26:19Z","timestamp":1787502379542,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijcard.2022.06.054","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T11:31:42Z","timestamp":1655983902000},"page":"138-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na+\/H+ exchanger-1"],"prefix":"10.1016","volume":"363","author":[{"given":"Hana E.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan D.","family":"Tune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren J.","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca S.","family":"Blaettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Kowala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Fliegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam G.","family":"Goodwill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2022.06.054_bb0005","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0008-6363(02)00836-2","article-title":"Role of the cardiac Na+\/H+ exchanger during ischemia and reperfusion","volume":"57","author":"Allen","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.biopen.2016.01.001","article-title":"Assessing Na(+)\/H(+) exchange and cell effector functionality in metastatic breast cancer","volume":"2","author":"Amith","year":"2016","journal-title":"Biochim. Open."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bcp.2016.08.010","article-title":"KR-33028, a potent inhibitor of the Na(+)\/H(+) exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells","volume":"118","author":"Amith","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0020","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030629","article-title":"Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system","volume":"20","author":"Ansary","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0030","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0735-1097(02)01693-5","article-title":"Na(+)\/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospects","volume":"39","author":"Avkiran","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(97)01371-X","article-title":"Antiarrhythmic effects of cariporide, a novel Na+-H+ exchange inhibitor, on reperfusion ventricular arrhythmias in rat hearts","volume":"339","author":"Aye","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0040","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijcard.2022.06.054_bb0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00395-019-0733-2","article-title":"Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization","volume":"114","author":"Baker","year":"2019","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0060","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0065","article-title":"Off-target effects of SGLT2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart","author":"Chung","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvab184","article-title":"SGLT2 inhibitors and the cardiac Na+\/H+ exchanger-1: the plot thickens","author":"Chung","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0075","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0080","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0022-2828(90)91474-L","article-title":"Interrelations between coronary artery pressure, myocardial metabolism and coronary blood flow","volume":"22","author":"Feigl","year":"1990","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0085","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2022.06.054_bb0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.13611","article-title":"A safety update on sodium glucose co-transporter 2 inhibitors","volume":"21","author":"Fitchett","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0095","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1111\/j.1540-8159.1996.tb03275.x","article-title":"Role of Na(+)-H+ exchange on reperfusion related myocardial injury and arrhythmias in an open-chest swine model","volume":"19","author":"Fukuta","year":"1996","journal-title":"Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24091765","article-title":"Sodium-hydrogen exchanger Isoform-1 inhibition: a promising pharmacological intervention for resuscitation from cardiac arrest","volume":"24","author":"Gazmuri","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ijcard.2022.06.054_bb0105","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1242\/jeb.01109","article-title":"A unique pathway of cardiac myocyte death caused by hypoxia-acidosis","volume":"207","author":"Graham","year":"2004","journal-title":"J. Exp. Biol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0110","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1006\/jmcc.1999.1029","article-title":"Blocking Na(+)-H+ exchange by cariporide reduces Na(+)-overload in ischemia and is cardioprotective","volume":"31","author":"Hartmann","year":"1999","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0115","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2022.06.054_bb0120","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijcard.2022.06.054_bb0125","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1006\/jmcc.2001.1435","article-title":"Role of cellular acidosis in production of nitric oxide in canine ischemic myocardium","volume":"33","author":"Kitakaze","year":"2001","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0130","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/01.CIR.102.16.1977","article-title":"Na(+)\/H(+) exchange inhibitor cariporide attenuates cell injury predominantly during ischemia and not at onset of reperfusion in porcine hearts with low residual blood flow","volume":"102","author":"Klein","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2022.06.054_bb0135","doi-asserted-by":"crossref","first-page":"12825","DOI":"10.1073\/pnas.202474099","article-title":"Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3","volume":"99","author":"Kubasiak","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats","volume":"18","author":"Lee","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","article-title":"SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart","volume":"4","author":"Lim","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0150","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3109\/10641969809052116","article-title":"Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 inhibitor cariporide (HOE 642)","volume":"20","author":"Linz","year":"1998","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0155","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11906-015-0551-3","article-title":"Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?","volume":"17","author":"Lovshin","year":"2015","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2337\/dc14-1596","article-title":"Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes","volume":"38","author":"Majewski","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2022.06.054_bb0165","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0170","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0175","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/iub.1323","article-title":"The Na(+) \/H(+) exchanger and pH regulation in the heart","volume":"66","author":"Odunewu-Aderibigbe","year":"2014","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ijcard.2022.06.054_bb0180","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/ejhf.1328","article-title":"Empagliflozin directly improves diastolic function in human heart failure","volume":"20","author":"Pabel","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0185","first-page":"C1158","article-title":"Impaired cell volume regulation in Na(+)-H+ exchange-deficient mutants","volume":"257","author":"Rotin","year":"1989","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0190","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/01.CIR.101.25.2902","article-title":"Cardioprotective effects of the Na(+)\/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA","volume":"101","author":"Rupprecht","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2022.06.054_bb0195","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0205","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1161\/CIRCULATIONAHA.119.045033","article-title":"Implications of altered ketone metabolism and therapeutic ketosis in heart failure","volume":"141","author":"Selvaraj","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2022.06.054_bb0210","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/pedi.12626","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes","volume":"19","author":"Tamborlane","year":"2018","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.ijcard.2022.06.054_bb0215","first-page":"59","article-title":"Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the guard during ischemia against necrosis (GUARDIAN) trial","volume":"1","author":"Theroux","year":"2000","journal-title":"Curr. Control Trials Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.13024","article-title":"Empagliflozin inhibits Na(+) \/H(+) exchanger activity in human atrial cardiomyocytes","author":"Trum","year":"2020","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0225","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijcard.2022.06.054_bb0230","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0235","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0240","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0245","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.26851","article-title":"Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways","volume":"234","author":"Yaribeygi","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0250","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0735-1097(01)01608-4","article-title":"The Na(+)\/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial","volume":"38","author":"Zeymer","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0255","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.06.054_bb0260","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvab129","article-title":"SGLT2 inhibitor empagliflozin inhibits the cardiac Na+\/H+ exchanger 1: persistent inhibition under various experimental conditions","author":"Zuurbier","year":"2021","journal-title":"Cardiovasc. Res."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322010063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322010063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:58:35Z","timestamp":1759093115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527322010063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":52,"alternative-id":["S0167527322010063"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.06.054","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na+\/H+ exchanger-1","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.06.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}